Liposomal Bupivacaine (Exparel) for Postoperative Pain Control for Open and Laparoscopic Abdominal Hernia Repair
Liposomal Bupivacaine (Exparel) for Postoperative Pain Control for Open and Laparoscopic Abdominal Hernia Repair
The purpose of this study is to learn how well Liposomal Bupivacaine (Exparel™) controls
 post-operative pain in patients undergoing both open and laparoscopic (minimally invasive)
 abdominal hernia repair surgery.
When a person has surgery, there are a few different standard care options for pain relief.
 Anesthetic (numbing) drugs can be used to cause a loss of feeling in or around a wound but
 the effect of the numbing medication can be undone.Pain relieving drugs such as acetaminophen
 (Tylenol), non-steroidal anti-inflammatory drugs (NSAIDs), and opioid (narcotic) medications
 can also be taken by mouth or through a vein in your arm (intravenous IV.) However, both
 NSAIDs & Opioid drugs can produce negative side effects such as serious difficulty breathing,
 stopping breathing altogether, low blood pressure, nausea, vomiting, itching, and
 constipation.

 Bupivacaine is one of the commonly used longer-acting numbing medicines (anesthetics). The
 effect of Bupivacaine or other anesthetics is limited to usually no more than 12 hours when
 injected around the area of the incision during surgery. Liposomal Bupivacaine (Exparel)
 could provide good, continuous and longer pain relief than current therapies/treatments
 commonly used. This can possibly improve patient satisfaction and time to normal activities
 such as walking.
Inclusion Criteria:

 -  Patients scheduled to undergo an open or laparoscopic abdominal hernia repair.

 -  Ability to provide informed consent, adhere to study visit schedule, and complete all
 study assessments.

 Exclusion Criteria:

 -  Patients with a history of hypersensitivity or idiosyncratic reactions or intolerance
 to any local anesthetic, opioids or ketorolac.

 -  Patients who abuse alcohol or other drug substance.

 -  Patients who are on chronic opioid therapy (taken an opioid 5 of the last 7 days).

 -  Patients with severe hepatic impairment.

 -  Patients currently pregnant.